Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) Stock
—
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
About Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
—
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is led by CEO Lei Wang, employs 3,890 people, headquartered in Tianjin, CN, publicly traded since 2001.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) stock trades at $41.60 with a market capitalization of $31.44B. The stock is valued at a price-to-earnings (P/E) ratio of 36.77, price-to-book of 5.29, price-to-sales of 6.66. Over the past 52 weeks the stock has ranged between $33.83 and $50.95, and currently trades 18.4% below its 52-week high. It pays a dividend yielding 11.71%.
On profitability, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited generates a return on equity (ROE) of 11.28%, an operating margin of 21.87%, a net profit margin of 17.96%.
The balance sheet shows a debt-to-equity ratio of 0.02 (debt below half of shareholders' equity), a current ratio of 1.38.
600329.SS has an average daily trading volume of 2,801,932 shares, a beta of 0.53 (historically less volatile than the overall market), 0.57B shares outstanding.
Official website: www.jydrt.com.cn
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) — frequently asked questions
What is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) stock price today?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) is currently trading at $41.60, up 11.83% today.
What is 600329.SS P/E ratio?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's P/E ratio is 36.77. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.
What is 600329.SS return on equity (ROE)?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's return on equity (ROE) is 11.28%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.
What is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's market cap?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has a market capitalization of $31.44B.
Does 600329.SS pay a dividend?
Yes. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited currently yields 11.71%. Yield moves with the share price, so it changes daily even when the payment does not.
How much debt does 600329.SS carry?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has a debt-to-equity ratio of 0.02. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 600329.SS's profit margin?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited reports a net profit margin of 17.96% — the share of revenue left after every cost, including tax and interest.
What sector is 600329.SS in?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is classified under —, in the — industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 600329.SS listed on?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited trades on SHH under the ticker 600329.SS.
What is 600329.SS's 52-week range?
Over the last year Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has traded between $33.83 and $50.95.
Related — Stocks
Popular Stocks
Screens 600329.SS currently matches
On the figures above, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited passes the filters for 22 of our ready-made screens, among them High Dividend Stocks, Dividend Stocks, High Yield Dividend Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.